Diss. (sammanfattning) Umeå : Umeå universitet, 2005. / Härtill 4 uppsatser.

Thesis (doctoral)--University of Wisconsin-Madison, 2000. / Includes bibliographical references.

Research Project (M.B.A.) - Simon Fraser University, 2007. / Theses (Faculty of Business Administration) / Simon Fraser University. Senior supervisor: Dr. Aidan Vining -- Faculty of Business Administration. MBA-MOT Program. Also issued in digital format and available on the World Wide Web.

Thesis (doctoral)--University of Wisconsin-Madison, 2000. / eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references.

Lai Ching Ha. / Thesis (Ph.D.)--Chinese University of Hong Kong, 1995. / Includes bibliographical references (leaves 225-243). / Title --- p.1 / Abstract --- p.2 / Acknowledgments --- p.4 / Contents --- p.5 / Abbreviations --- p.10 / List of Figures --- p.12 / List of Tables --- p.15 / Chapter Chapter 1 --- Review on Inherited Metabolic Diseases --- p.18 / Chapter 1.1 --- Development of the concept of inherited metabolic diseases (IMD) --- p.18 / Chapter 1.2 --- Frequency of inherited metabolic diseases --- p.20 / Chapter 1.3 --- Molecular basis of mutations in inherited metabolic diseases --- p.22 / Chapter 1.3.1 --- Point mutations --- p.22 / Chapter 1.3.2 --- Small deletions and insertions --- p.25 / Chapter 1.3.3 --- large deletions or duplications --- p.26 / Chapter 1.4 --- Pathological consequences of protein defect resultingin IMD --- p.27 / Chapter 1.4.1 --- End product --- p.28 / Chapter 1.4.2 --- Precursor accumulation --- p.28 / Chapter 1.4.3 --- Unusual metabolites --- p.29 / Chapter 1.5 --- Heterogeneity of inherited metabolic diseases --- p.29 / Chapter 1.5.1 --- Genetic heterogeneity --- p.29 / Chapter 1.5.2 --- Variations of expression in different cells --- p.31 / Chapter 1.6 --- Diagnosis of inherited metabolic diseases --- p.32 / Chapter 1.6.1. --- Biochemical investigations --- p.32 / Chapter 1.6.2 --- Identification of accumulated or missing metabolites --- p.33 / Chapter 1.6.3 --- Direct analysis of enzymes and proteins --- p.34 / Chapter 1.6.4 --- Molecular investigations --- p.34 / Chapter 1.7 --- Treatment of inherited metabolic diseases --- p.40 / Chapter 1.7.1 --- Treatment at the clinical phenotype level --- p.41 / Chapter 1.7.2 --- Treatment at the metabolite level --- p.41 / Chapter 1.7.3 --- Treatment at the dysfunctional protein level --- p.43 / Chapter 1.7.4 --- Transplantation --- p.44 / Chapter 1.7.5 --- Gene therapy --- p.45 / Chapter 1.8 --- Inherited metabolic diseases in Hong Kong --- p.47 / Chapter 1.9 --- General Aim --- p.48 / Chapter Chapter 2 --- Study of Inherited Metabolic Diseases in Mentally Retarded Patients --- p.49 / Chapter 2.1 --- Introduction --- p.49 / Chapter 2.2 --- Aim --- p.52 / Chapter 2.3 --- Materials --- p.53 / Chapter 2.3.1 --- Standards --- p.53 / Chapter 2.3.2 --- Chemical reagents --- p.53 / Chapter 2.3.3 --- Derivatization reagents --- p.54 / Chapter 2.3.4 --- Major equipment --- p.54 / Chapter 2.4 --- Clinical materials --- p.56 / Chapter 2.4.1 --- Subjects --- p.55 / Chapter 2.4.2 --- Blood and urine samples --- p.56 / Chapter 2.5 --- Methods --- p.57 / Chapter 2.5.1 --- General biochemistry tests --- p.57 / Chapter 2.5.2 --- Metabolic screening tests --- p.57 / Chapter 2.5.3 --- Two-dimensional thin layer chromatography --- p.53 / Chapter 2.5.4 --- Identification of urinary organic acids by gas chromatography mass spectroscopy --- p.59 / Chapter 2.5.5 --- Amino acid analysis by high performance liquid chromatography --- p.66 / Chapter 2.6 --- Results --- p.71 / Chapter (A) --- Methodological Aspects / Chapter 2.6.1 --- Identification of urinary organic acids by gas chromatography-mass spectroscopy (GC-MS) --- p.71 / Chapter 2.6.2 --- Amino acid analysis by high performance liquid chromatography (HPLC) --- p.86 / Chapter (B) --- Patient Investigations / Chapter 2.6.3 --- General biochemistry tests --- p.107 / Chapter 2.6.4 --- Serum amino acid profiles --- p.113 / Chapter 2.6.5 --- Urinary organic acid analysis --- p.115 / Chapter 2.6.6 --- Case reports --- p.119 / Chapter 2.7 --- Discussion --- p.123 / Chapter 2.7.1 --- Identification of urinary organic acids by gas chromatography-mass spectroscopy (GC-MS) --- p.123 / Chapter 2.7.2. --- Amino acid analysis by high performance liquid chromatography (HPLC) --- p.130 / Chapter 2.7.3 --- Identification of inherited metabolic diseases (IMD)in an institutionalized mentally retarded patients --- p.136 / Chapter Chapter 3 --- Molecular Investigation of Maple Syrup Urine Disease --- p.140 / Chapter 3.1 --- Introduction --- p.140 / Chapter 3.1.1 --- Branched chain amino acids (BCAA) --- p.140 / Chapter 3.1.2 --- Metabolism of branched chain amino acids --- p.142 / Chapter 3.1.3 --- Maple syrup urine disease (MSUD) --- p.144 / Chapter 3.1.4 --- Classification of maple syrup urine disease --- p.146 / Chapter 3.1.5 --- Screening and diagnosis of maple syrup urine disease --- p.148 / Chapter 3.1.6 --- Treatment of maple syrup urine disease --- p.150 / Chapter 3.1.7. --- Branched chain a-ketoacid dehydrogenase complex (BCKDH) --- p.151 / Chapter 3.1.8 --- "Gene features of human E1α,E1β and E2 subunitsin branched chain α-ketoacid dehydrogenase complex" --- p.153 / Chapter 3.1.9 --- Molecular defects of the BCKDH gene complex --- p.156 / Chapter 3.1.10 --- MSUD in Hong Kong --- p.161 / Chapter 3.2 --- Aim --- p.163 / Chapter 3.3 --- Materials --- p.164 / Chapter 3.3.1 --- Source of skin fibroblasts --- p.164 / Chapter 3.3.2 --- Enzymes --- p.164 / Chapter 3.3.3 --- DNA markers --- p.164 / Chapter 3.3.4 --- Reagent Kits --- p.165 / Chapter 3.3.5 --- Primers --- p.165 / Chapter 3.3.6 --- Chemical reagents --- p.165 / Chapter 3.3.7 --- Nitrocellulose membrane --- p.166 / Chapter 3.3.8 --- Antiserum for Western blotting --- p.166 / Chapter 3.3.9 --- Radioisotopes --- p.166 / Chapter 3.4 --- Methods --- p.168 / Chapter 3.4.1 --- Preparation of buffers and solutions --- p.168 / Chapter 3.4.2 --- Agarose gel electrophoresis --- p.170 / Chapter 3.4.3 --- Preparation of native polyacrylamide gel --- p.171 / Chapter 3.4.4 --- Preparation of sodium dodecyl sulfate (SDS) polyacrylamide gel --- p.172 / Chapter 3.4.5 --- Preparation of denaturing polyacrylamide gel --- p.173 / Chapter 3.4.6 --- Branched chain α-ketoacid dehydrogenase complex enzyme assay --- p.173 / Chapter 3.4.7. --- Identification of the affected subunits in BCKDH complex of MSUD patient and her family members --- p.176 / Chapter 3.4.8 --- Screening of mutation in the BCKDH subunits by RT-PCR-SSCP --- p.178 / Chapter 3.4.9 --- Mutation analysis of whole cDNA fragments of Elα， Elβ and E2 subunits by ds DNA cycle sequencing --- p.184 / Chapter 3.5 --- Results --- p.188 / Chapter 3.5.1 --- Branched chain α-ketoacid dehydrogenase complex enzyme assay --- p.188 / Chapter 3.5.2 --- Identification of the affected subunits in BCKDH complex ofMSUD patient and her family members --- p.188 / Chapter 3.5.3 --- Screening of mutation in the BCKDH subunits by RT-PCR-SSCP --- p.192 / Chapter 3.5.4 --- "Mutation analysis of whole cDNA fragments of Ela, Elβ and E2 subunits by ds DNA cycle sequencing" --- p.204 / Chapter 3.6 --- Discussion --- p.210 / Chapter 3.6.1 --- BCKDH activity in the MSUD patient and her family members --- p.210 / Chapter 3.6.2 --- Investigation of the mutation sites --- p.212 / General Conclusion --- p.222 / Appendix --- p.224 / References --- p.225

by Chan Chuek Kee. / Thesis (Ph.D.)--Chinese University of Hong Kong, 1992. / Includes bibliographical references (leaves 165-201). / Abstract --- p.i / Table of Content --- p.iv / List of Abbreviations --- p.viii / List of Tables --- p.x / List of Figures --- p.xii / Acknowledgement --- p.xiii / Chapter Chapter 1. --- Introduction / Chapter 1.1. --- Discovery and historical events --- p.1 / Chapter 1.2. --- General characteristics of rotavirus --- p.3 / Chapter 1.2.1. --- Virus morphology --- p.3 / Chapter 1.2.2. --- Physicochemical properties --- p.3 / Chapter 1.2.3. --- Virus stability and inactivation --- p.4 / Chapter 1.2.4. --- Genome structure --- p.4 / Chapter 1.2.5. --- Rotavirus proteins --- p.5 / Chapter 1.2.6. --- Morphogenesis --- p.8 / Chapter 1.3. --- Characteristics of rotavirus infection --- p.9 / Chapter 1.3.1. --- Morbidity and mortality --- p.9 / Chapter 1.3.2. --- Clinical features --- p.11 / Chapter 1.3.3. --- Pathogenesis --- p.13 / Chapter 1.3.4. --- Seasonal variation of rotavirus infection --- p.13 / Chapter 1.3.5. --- Nosocomial rotavirus infection --- p.14 / Chapter 1.3.6. --- Route of transmission --- p.14 / Chapter 1.4. --- Classification and epidemiology of rotaviruses --- p.15 / Chapter 1.4.1. --- Rotavirus groups --- p.15 / Chapter 1.4.2. --- Rotavirus subgroups --- p.16 / Chapter 1.4.3. --- Rotavirus serotypes --- p.17 / Chapter 1.4.4. --- Rotavirus electropherotypes --- p.20 / Chapter 1.4.5. --- "Relationship between subgroup, serotype and electropherotype" --- p.23 / Chapter 1.4.6. --- Mechanisms contributing to strain variations --- p.24 / Chapter 1.5. --- Detection of rotavirus --- p.28 / Chapter 1.5.1. --- Electron microscopy (EM) --- p.28 / Chapter 1.5.2. --- Virus isolation --- p.29 / Chapter 1.5.3. --- Serological methods --- p.30 / Chapter 1.5.4. --- RNA analysis --- p.30 / Chapter 1.5.5. --- Nucleic acid hybridization --- p.31 / Chapter 1.6. --- Prevention and control of rotavirus infection --- p.32 / Chapter 1.6.1. --- Host resistance --- p.32 / Chapter 1.6.2. --- Vaccine development --- p.33 / Chapter 1.6.3. --- Passive immunization --- p.35 / Chapter 1.7. --- Objectives of this study --- p.36 / Chapter Chapter 2. --- Materials and methods / Chapter 2.1. --- Materials --- p.38 / Chapter 2.1.1. --- Reagents for tissue culture work --- p.38 / Chapter 2.1.2. --- Reagents for electropherotyping --- p.39 / Chapter 2.1.3. --- Reagents for ELISA --- p.42 / Chapter 2.1.4. --- Reagents for hybridization assay --- p.43 / Chapter 2.2. --- Methods / Chapter 2.2.1. --- Collection of specimens --- p.46 / Chapter 2.2.2. --- Rotavirus strains --- p.46 / Chapter 2.2.3. --- Monoclonal antibodies --- p.48 / Chapter 2.2.4. --- Detection of rotavirus antigen by ELISA --- p.49 / Chapter 2.2.5. --- Rotavirus electropherotyping --- p.50 / Chapter 2.2.6. --- Serotyping of rotavirus by fluorescent foci neutralization --- p.52 / Chapter 2.2.7. --- Serotyping of rotavirus by oligo- nucleotide probes hybridization --- p.55 / Chapter 2.2.8. --- Rotavirus serotyping by ELISA --- p.59 / Chapter 2.2.9. --- Rotavirus subgrouping by ELISA --- p.61 / Chapter Chapter 3. --- Results / Chapter 3.1. --- Age and sex distribution of the study population --- p.63 / Chapter 3.2. --- Detection of rotavirus by ELISA --- p.63 / Chapter 3.3. --- Seasonal distribution of rotavirus infections --- p.67 / Chapter 3.4. --- Genetic diversity of human rotaviruses --- p.74 / Chapter 3.5. --- Subgroup determination by ELISA --- p.99 / Chapter 3.6. --- Rotavirus serotypes by fluorescent foci neutralization (FFN) --- p.102 / Chapter 3.7. --- Rotavirus serotypes by ELISA --- p.107 / Chapter 3.8. --- Rotavirus serotypes as determined by oligonucleotide probes --- p.110 / Chapter 3.8.1. --- Dot hybridization --- p.110 / Chapter 3.8.2. --- Northern blots of electrophoresed RNAs --- p.118 / Chapter 3.9. --- Temporal distribution of rotavirus serotypes --- p.124 / Chapter 3.10. --- "Association between serotype, subgroups and electropherotypes" --- p.128 / Chapter 3.11. --- Unusual rotavirus strains --- p.135 / Chapter 3.12. --- Nosocomial rotavirus infection --- p.135 / Chapter Chapter 4. --- Discussion / Chapter 4.1. --- Seasonal variation of rotavirus infection --- p.141 / Chapter 4.2. --- Molecular epidemiology of rotavirus infection --- p.143 / Chapter 4.3. --- Subgrouping of human rotavirus strains --- p.146 / Chapter 4.4. --- Serotyping rotaviruses by ELISA --- p.147 / Chapter 4.5. --- Serotyping rotaviruses by oligonucleotide probe hybridization --- p.150 / Chapter 4.6 --- Advantage and disadvantage of different methods for serotyping of rotaviruses --- p.152 / Chapter 4.7. --- Distribution of rotavirus serotypes --- p.153 / Chapter 4.8. --- Association between rotavirus serotype and electropherotype --- p.156 / Chapter 4.9. --- Nosocomial rotavirus infection --- p.158 / Chapter 4.10. --- Unusual rotavirus strains --- p.159 / Chapter 4.11. --- Concluding remark --- p.162 / Chapter 4.12. --- Future studies --- p.164 / References --- p.165

Diss. (sammanfattning)--Linköping : Linköpings universitet, 2006. / Härtill 4 uppsatser.

Thesis (Ph. D.)--University of Washington, 1998. / Vita. Includes bibliographical references (p. [119]-127).

Akademisk avhandling--Uppsala. / Extra t.p., with thesis statement, inserted. Bibliography: p. 55-60.

Familial hypercholesterolemia (FH) is an autosomal dominant disorder in which the primary defect is a mutation in the LDL receptor. Heterozygous FH is among the most common inborn errors of metabolism and remains as the best example of an inherited defect causing premature coronary artery disease (CAD). This thesis describes the physical and biochemical characteristics of heterozygous FH in a large cohort consisting of 208 women and 156 men. The influence of both genetic and environmental factors on the clinical expression of FH were investigated to better understand the phenotypic variation within FH and thus improve the prediction and treatment of CAD in affected individuals. The general incidence of CAD in this population was lower compared to previous reports but the differences between the sexes were expected. It was shown that men had a much higher frequency of CAD (31%) compared to women (13%) despite having lower concentrations of total and LDL cholesterol. In addition, the average age of onset of coronary symptoms was delayed in females, 55 years compared to 48 years for males. A greater risk of developing CAD for men was associated with low levels of HDL cholesterol and a history of smoking. In women, however, CAD was associated with elevated triglyceride levels and the presence of hypertension. In order to efficiently assess the influence of the co-inheritance of the apolipoprotein E polymorphism in this large FH population, a novel apo E phenotyping procedure was developed. Phenotypes were determined directly from plasma which was neuraminidase treated, delipidated and focused in polyacrylamide minigels. The accuracy of this method was confirmed by making a comparison to the established procedure of phenotyping by isoelectric focusing of delipidated VLDL. The low cost, speed and simplicity of the minigel methodology provided ideal conditions to phenotype a large patient population. The frequencies of the ɛ2, ɛ3 and ɛ4 alleles of apolipoprotein E in 125 unrelated FH subjects did not differ significantly from the normal population. In addition, there was no apparent relationship between apo E4 and the concentration of any of the parameters in the plasma lipid profile. However, the presence of the E2 isoform was associated with significantly elevated triglycerides in both sexes. From this study, it is evident that the mutant FH gene exerts its effect within a system of interacting environmental and polygenic factors that are known to modify atherosclerotic risk. It has been established that the dissimilarity in the frequency of CAD between men and women is related to differences between the impact of known risk factors and the incidence of CAD. Therefore, the importance of the influence of these risk factors and the differences between men and women should be emphasized when treating and predicting the development of CAD in patients with FH. / Medicine, Faculty of / Pathology and Laboratory Medicine, Department of / Graduate